---
title: "20/20 Biolabs, Inc. (AIDX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AIDX.US.md"
symbol: "AIDX.US"
name: "20/20 Biolabs, Inc."
industry: "Health Care Supplies"
---

# 20/20 Biolabs, Inc. (AIDX.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Location | US Market |
| Website | [2020biolabs.com](https://2020biolabs.com) |

## Company Profile

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, incl...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-28T04:30:15.000Z

**Overall: D (0.64)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 41 / 45 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 31.74% |  |
| Net Profit YoY | 42.31% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 644.99 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 39.53M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.04M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | -159.33% | E |
| Gross Margin | 34.71% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 31.74% | A |
| Net Profit YoY | 42.31% | B |
| Total Assets YoY | 0.00% | C |
| Net Assets YoY | 0.00% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -62.76% | D |
| OCF YoY | 31.74% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 96.65% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 20/20 Biolabs, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-159.33%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "34.71%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "31.74%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "42.31%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-62.76%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "31.74%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "96.65%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Essilor (US.ESLOY) | B | B | C | B | B | B |
| 02 | Medline (US.MDLN) | C | B | B | C | B | B |
| 03 | HOYA Corporation (US.HOCPY) | A | B | B | A | C | B |
| 04 | Align (US.ALGN) | B | C | B | B | C | B |
| 05 | Merit Medical (US.MMSI) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.14 | 40/45 | - | - | - |
| PB | 644.99 | 40/45 | - | - | - |
| PS (TTM) | 19.35 | 38/45 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/AIDX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AIDX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AIDX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.